Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 199.

Pauli, C; Moch, H; Rubin, M A (2017). Etablierung einer Living Biobank. Der Pathologe:Epub ahead of print.

Rodewald, A K; Bode, P; Cathomas, G; Moch, H (2017). Klinische Obduktionen in der Schweiz: ein Statusbericht. Der Pathologe, 38(5):416-421.

Moch, H (2016). WHO-ISUP-Graduierungssystem für Nierenkarzinome. Der Pathologe, 37(4):355-360.

Moch, H (2016). Nierentumoren. Der Pathologe, 37(2):125-126.

Paner, G; Amin, M B; Moch, H; Störkel, S (2016). Chromophobe renal cell carcinoma. In: Moch, H; Humphrey, P A; Ulbright, T M; Reuter, V E. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC), 27-28.

Moch, H; Bonsib, S M; Delahunt, B; Eble, J N; Egevad, L; Grignon, D J; Linehan, W M; Reuter, V E; Srigley, J R; Sulser, T; Tan, P H (2016). Clear cell renal cell carcinoma. In: Moch, H; Humphrey, P A; Ulbright, T M; Reuter, V E. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC), 18-21.

Moch, H; Amin, M B; Srigley, J R (2016). Germ cell tumours. In: Moch, H; Humphrey, P A; Ulbright, T M; Reuter, V E. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC), 75.

Delahunt, B; Cheville, J; Moch, H (2016). Haemangioblastoma. In: Moch, H; Humphrey, P A; Ulbright, T M; Reuter, V E. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC), 67.

Cubilla, A L; Amin, M B; Ayala, A; Ayala, G; Chaux, A; Corbishley, C; Dillner, J; Moch, H; Sanchez, D F; Soares, F A; Tamboli, P; Young, R H (2016). Malignant epithelial tumours of the penis. In: Moch, H; Humphrey, P A; Ulbright, T M; Reuter, V E. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC), 262-276.

Montinori, R; Cheng, L; Lopez-Beltran, A; Michal, M; Moch, H (2016). Multilocular cystic renal neoplasm of low malignant potential. In: Moch, H; Humphrey, P A; Ulbright, T M; Reuter, V E. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC), 22.

Moch, H; Cheville, J (2016). Neuroendocrine tumours. In: Moch, H; Humphrey, P A; Ulbright, T M; Reuter, V E. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC), 72-73.

Hes, O; Moch, H; Reuter, V E (2016). Oncocytoma. In: Moch, H; Humphrey, P A; Ulbright, T M; Reuter, V E. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC), 43-44.

Eble, J N; Moch, H; Amin, M B; Argani, P; Cheville, J; Delahunt, B; Martignoni, G; Srigley, J R; Tan, P H; Tickoo, S K (2016). Papillary adenoma. In: Moch, H; Humphrey, P A; Ulbright, T M; Reuter, V E. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC), 42-43.

Delahunt, B; Algabe, F; Cheville, J; Amin, M B; Argani, P; Martignoni, G; Moch, H; Srigley, J R; Tan, P H; Tickoo, S K (2016). Papillary renal cell carcinoma. In: Moch, H; Humphrey, P A; Ulbright, T M; Reuter, V E. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC), 23-25.

Velàzques, E F; Amin, M B; Cubilla, A L; Jenkins, D; Moch, H; Piris, A; Quint, W G V (2016). Precursor lesions of the penis. In: Moch, H; Humphrey, P A; Ulbright, T M; Reuter, V E. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC), 277-279.

Moch, H; Amin, M B; Argani, P; Cheville, J; Delahunt, B; Martignoni, G; Medeiros, L J; Srigley, J R; Tan, P H; Tickoo, S K (2016). Renal cell tumours. In: Moch, H; Humphrey, P A; Ulbright, T M; Reuter, V E. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC), 14-43.

Amin, M B; Moch, H; Alkan, S; Marques Maggio, E (2016). Renal haematopoietic neoplasms. In: Moch, H; Humphrey, P A; Ulbright, T M; Reuter, V E. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC), 73-75.

Nowicka, A M; Häuselmann, I; Borsig, L; Bolduan, S; Schindler, M; Schraml, P; Heikenwalder, M; Moch, H (2016). A novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization. Oncogene, 35(24):3125-3138.

Rausch, S; Scharpf, M; Moch, H; Stenzl, A; Bedke, J (2016). Leiomyomatöses Nierenzellkarzinom Kontroverse um eine neue Tumorentität. Der Urologe. Ausg. A, 55(3):376-380.

Frauchiger, A L; Mangana, J; Rechsteiner, M; Moch, H; Seifert, Burkhardt; Braun, R; Dummer, R; Goldinger, S M (2016). Prognostic relevance of LDH and serum S-100 levels in Stage IV melanoma with known BRAF mutation status. British Journal of Dermatology, 174(4):823-830.

Feilchenfeldt, J; Varga, Z; Siano, M; Grabsch, H I; Held, U; Schuknecht, B; Trip, A; Hamaguchi, T; Gut, P; Balague, O; Khanfir, K; Diebold, J; Jochum, W; Shoji, H; Kushima, R; Wagner, D; Shimada, Y; Cats, A; Knuth, A; Moch, H; Aebi, S; Hofer, S (2015). Corrigendum: Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). British Journal of Cancer, 113(12):1747.

Feilchenfeldt, J; Varga, Z; Siano, M; Grabsch, H I; Held, U; Schuknecht, B; Trip, A; Hamaguchi, T; Gut, P; Balague, O; Khanfir, K; Diebold, J; Jochum, W; Shoji, H; Kushima, R; Wagner, D; Shimada, Y; Cats, A; Knuth, A; Moch, H; Aebi, S; Hofer, S (2015). Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). British Journal of Cancer, 113(5):716-721.

Fankhauser, C D; Curioni-Fontecedro, A; Allmann, V; Beyer, J; Tischler, V; Sulser, T; Moch, H; Bode, P K (2015). Frequent PD-L1 expression in testicular germ cell tumors. British Journal of Cancer, 113(3):411-413.

Rechsteiner, M; Wild, P; Kiessling, M K; Bohnert, A; Zhong, Q; Stahel, R A; Moch, H; Curioni-Fontecedro, A (2015). A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib. Annals of Oncology, 26(1):246-248.

Huber, F; Montani, M; Sulser, T; Jaggi, R; Wild, P; Moch, H; Gevensleben, H; Schmid, M; Wyder, S; Kristiansen, G (2015). Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer-what has gone wrong? A blueprint for the way forward in biomarker studies. British Journal of Cancer, 112:140-148.

Curioni-Fontecedro, A; Pitocco, R; Schoenewolf, N L; Holzmann, D; Soldini, D; Dummer, R; Calvieri, S; Moch, H; Mihic-Probst, D; Fitsche, A (2015). Intratumoral heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 expression in mucosal melanoma. BioMed Research International, 2015:432479.

Curioni-Fontecedro, A; Soldini, D; Seifert, B; Eichmueller, T; Korol, D; Moch, H; Weder, W; Stahel, R (2014). A Comprehensive Analysis of Markers for Neuroendocrine Tumors of the Lungs Demonstrates Estrogen Receptor Beta to be a Prognostic Markers in SCLC Male Patients. Journal of Cytology & Histology:5:268.

Wyler, L; Napoli, C U; Ingold, B; Sulser, T; Heikenwälder, M; Schraml, P; Moch, H (2014). Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression. British Journal of Cancer, 110(3):686-694.

Berens, S; Vogt, P; Alkadhi, H; Berger, N; Moch, H (2014). Das schilddrüsenähnliche follikuläre Nierenzellkarzinom. Der Pathologe, 35(1):83-87.

Bode, P K; Moch, H (2014). Seminome des Hodens : Klassisch und weniger klassisch. Der Pathologe, 35(3):224-231.

Rauch, P J; Müllhaupt, B; Biedermann, L; Manz, M G; Ruschitzka, F; Flammer, A; Segerer, S T; Mohebbi, N; Jung, H H; Moch, H; Ikenberg, K; Aguzzi, A; Nuvolone, M; Distler, O; Rauch, A; Fehr, T H; Gerber, B (2014). Systemische Amyloidosen. Swiss Medical Forum, 14(50):943-948.

Tordella, L; Koch, S; Salter, V; Pagotto, A; Doondeea, J B; Feller, S M; Ratnayaka, I; Zhong, S; Goldin, R D; Lozano, G; McKeon, F D; Tavassoli, M; Fritzsche, F; Huber, G F; Rössle, M; Moch, H; Lu, X (2013). ASPP2 suppresses squamous cell carcinoma via RelA/p65-mediated repression of p63. Proceedings of the National Academy of Sciences of the United States of America, 110(44):17969-17974.

Rössle, M; Weber, C S; Züllig, L; Graf, N; Jochum, W; Stöckli, S J; Moch, H; Huber, G F (2013). EGFR expression and copy number changes in low T-stage oral squamous cell carcinomas. Histopathology, 63(2):271-278.

Züllig, L; Roessle, M; Weber, C; Graf, N; Haerle, S K; Jochum, W; Stoeckli, S J; Moch, H; Huber, G F (2013). High sex determining region Y-box 2 expression is a negative predictor of occult lymph node metastasis in early squamous cell carcinomas of the oral cavity. European Journal of Cancer, 49(8):1915-1922.

Broglie, M A; Soltermann, A; Rohrbach, D; Haile, S R; Pawlita, M; Studer, G; Huber, G F; Moch, H; Stoeckli, S J (2013). Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity-modulated chemoradiation. Head and Neck, 35(12):1698-1706.

Roth, P; Silginer, M; Goodman, S L; Hasenbach, K; Thies, S; Maurer, G; Schraml, P; Tabatabai, G; Moch, H; Tritschler, I; Weller, M (2013). Integrin control of the transforming growth factor-β pathway in glioblastoma. Brain, 136(2):564-576.

Eichelberg, C; Minner, S; Isbarn, H; Burandt, E; Terracciano, L; Moch, H; Kell, A; Heuer, R; Chun, F K; Sauter, G; Fisch, M; Tennstedt, P (2013). Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma. World Journal of Urology, 31(4):847-853.

Vogetseder, A; Thies, S; Ingold, B; Roth, P; Weller, M; Schraml, P; Goodman, S L; Moch, H (2013). αv-Integrin isoform expression in primary human tumors and brain metastases. International Journal of Cancer, 133(10):2362-2371.

Moch, H; Kerjaschki, D; Kain, R; Ammann, K (2012). Niere. In: Böcker, W; Denk, H; Heitz, P U; Moch, H; Höfler, G; Kreipe, H. Pathologie. München: Urban & Fischer, Elsevier, 693-720.

Moch, Holger; Zimmermann, Dieter R; Probst-Hensch, Nicole (2012). Pathologie: Aufgaben und Methoden. In: Böcker, W; Denk, H; Heitz, P U; Höfler, G; Kreipe, H; Moch, H. Pathologie. München: Elsevier, Urban & Fischer, 3-19.

Moch, H; Höfler, H K; Lax, S; Moll, R; Tannapfel, A; Zimmermann, D R (2012). Tumorerkrankungen. In: Böcker, W; Denk, H; Heitz, P U; Höfler, G; Kreipe, H; Moch, H. Pathologie. München: Elsevier, Urban & Fischer, 123-169.

Moch, H (2012). Biomarker für Nierenkarzinome : Was ist gerechtfertigt? Der Pathologe, 33(2):278-281.

Reiner, C S; Goetti, R; Eberli, D; Klotz, E; Boss, A; Pfammatter, T; Frauenfelder, T; Moch, H; Sulser, T; Alkadhi, H (2012). CT perfusion of renal cell carcinoma: Impact of volume coverage on quantitative analysis. Investigative Radiology, 47(1):33-40.

Morra, L; Rechsteiner, M; Casagrande, S; von Teichman, A; Schraml, P; Moch, H; Soltermann, A (2012). Characterization of periostin isoform pattern in non-small cell lung cancer. Lung Cancer, 76(2):183-190.

Varga, Z; Tubbs, R R; Wang, Z; Sun, Y; Noske, A; Kradolfer, D; Bosshard, G; Jochum, W; Moch, H; Öhlschlegel, C (2012). Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer. Breast Cancer Research and Treatment, 132(3):925-935.

Denkert, C; Kronenwett, R; Schlake, W; Bohmann, K; Penzel, R; Weber, K E; Höfler, H; Lehmann, U; Schirmacher, P; Specht, K; Rudas, M; Kreipe, H H; Schraml, P; Schlake, G; Bago-Horvath, Z; Tiecke, F; Varga, Z; Moch, H; Schmidt, M; Prinzler, J; Kerjaschki, D; Sinn, B V; Müller, B M; Filipits, M; Petry, C; Dietel, M (2012). Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Archiv, 460(3):251-259.

Minner, S; Rump, D; Tennstedt, P; Simon, R; Burandt, E; Terracciano, L; Moch, H; Wilczak, W; Bokemeyer, C; Fisch, M; Sauter, G; Eichelberg, C (2012). Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer, 118(5):1268-1275.

von Moos, R; Seifert, B; Simcock, M; Goldinger, S M; Gillessen, S; Ochsenbein, A; Michielin, O; Cathomas, R; Schläppi, M; Moch, H; Schraml, P H; Mihic-Probst, D; Mamot, C; Schönewolf, N; Dummer, R (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of Oncology, 23(2):531-536.

Algaba, F; Delahunt, B; Berney, D M; Camparo, P; Compérat, E; Griffiths, D; Kristiansen, G; Lopez-Beltran, A; Martignoni, G; Moch, H; Montironi, R; Varma, M; Egevad, L (2012). Handling and reporting of nephrectomy specimens for adult renal tumours: a survey by the European Network of Uropathology. Journal of Clinical Pathology, 65(2):106-113.

Wiedl, T; Collaud, S; Hillinger, S; Arni, S; Burgess, C; Kroll, W; Schraml, P; Soltermann, A; Moch, H; Weder, W (2012). KRAS mutation is associated with elevated myeloblastin activity in human lung adenocarcinoma. Cancer Genomics & Proteomics, 9(1):51-54.

Moch, H; Blank, P R; Dietel, M; Elmberger, G; Kerr, K M; Palacios, J; Penault-Llorca, F; Rossi, G; Szucs, T D (2012). Personalized cancer medicine and the future of pathology. Virchows Archiv, 460(1):3-8.

Schraml, P; von Teichman, A; Mihic-Probst, D; Simcock, M; Ochsenbein, A; Dummer, R; Michieilin, O; Seifert, B; Schläppi, M; Moch, H; von Moos, R (2012). Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncology Reports, 28(2):654-658.

Brandt, S; Lohe, B; Vogetseder, A; Rüdiger, T; Moch, H; Bode, P (2012). Primitiver neuroektodermaler Tumor im Hoden: Molekulare Analyse und Diskussion der Entstehung. Der Pathologe:1-4.

Varga, Z; Moelans, C B; Zuerrer-Hardi, U; Ramach, C; Behnke, S; Kristiansen, G; Moch, H (2012). Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes. Breast Cancer Research and Treatment, 133(3):929-935.

Sharma, A; Bode, B; Wenger, R H; Lehmann, K; Sartori, A A; Moch, H; Knuth, A; von Boehmer, L; van den Broek, Maries (2011). Gamma-radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS ONE, 6(11):e28217.

Moch, H (2011). Dokumentation der diagnostischen Qualität im Krankenhaus: Auswertung der Autopsieberichte. Der Pathologe, 32(Sup 2):282-286.

Suwaki, N; Vanhecke, E; Atkins, K M; Graf, M; Swabey, K; Huang, P; Schraml, P; Moch, H; Cassidy, A M; Brewer, D; Al-Lazikani, B; Workman, P; De-Bono, J; Kaye, S B; Larkin, J; Gore, M E; Sawyers, C L; Nelson, P; Beer, T M; Geng, H; Gao, L; Qian, D Z; Alumkal, J J; Thomas, G; Thomas, G V (2011). A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Science Translational Medicine, 3(85):85ra47.

Noske, A; Zimmermann, A K; Caduff, R; Varga, Z; Fink, D; Moch, H; Kristiansen, G (2011). Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer. Virchows Archiv, 459(1):91-97.

Arbogast, S; Behnke, S; Opitz, I; Stahel, R A; Seifert, B; Weder, W; Moch, H; Soltermann, A (2011). Automated ERCC1 Immunohistochemistry in Non-small Cell Lung Cancer: Comparison of anti-ERCC1 Antibodies 8F1, D-10, and FL-297. Applied Immunohistochemistry & Molecular Morphology, 19(2):99-105.

Soltermann, A; Kilgus-Hawelski, S; Behnke, S; Storz, M; Moch, H; Bode, B (2011). Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10. Journal of Clinical Bioinformatics, 1:25.

Esterházy, D; Stützer, I; Wang, H; Rechsteiner, M P; Beauchamp, J; Döbeli, H; Hilpert, H; Matile, H; Prummer, M; Schmidt, A; Lieske, N; Boehm, B; Marselli, L; Bosco, D; Kerr-Conte, J; Aebersold, R; Spinas, G A; Moch, H; Migliorini, C; Stoffel, M (2011). Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass. Cell Metabolism, 14(3):365-377.

Walter, D; Satheesha, S; Albrecht, P; Bornhauser, B C; D'Alessandro, V; Oesch, S M; Rehrauer, H; Leuschner, I; Koscielniak, E; Gengler, C; Moch, H; Bernasconi, M; Niggli, F K; Schäfer, B W (2011). CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS ONE, 6(5):e19506.

Cima, I; Schiess, R; Wild, P; Kaelin, M; Schüffler, P; Lange, V; Picotti, P; Ossola, R; Templeton, A; Schubert, O; Fuchs, T; Leippold, T; Wyler, S; Zehetner, J; Jochum, W; Buhmann, J M; Cerny, T; Moch, H; Gillessen, S; Aebersold, R; Krek, W (2011). Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 108(8):3342-3347.

Brookman-May, S; May, M; Zigeuner, R; Shariat, S F; Scherr, D S; Chromecki, T; Moch, H; Wild, P J; Mohamad-Al-Ali, B; Cindolo, L; Wieland, W F; Schips, L; De Cobelli, O; Rocco, B; Santoro, L; De Nunzio, C; Tubaro, A; Coman, I; Feciche, B; Truss, M; Dalpiaz, O; Hohenfellner, M; Gilfrich, C; Wirth, M P; Burger, M; Pahernik, S (2011). Collecting system invasion and Fuhrman grade but not tumor size facilitate prognostic stratification of patients with pT2 renal cell carcinoma. Journal of Urology, 186(6):2175-2181.

Algaba, F; Akaza, H; Lopez-Beltran, A; Martignoni, G; Moch, H; Montironi, R; Reuter, V (2011). Current pathology keys of renal cell carcinoma. European Urology, 60(4):634-643.

Der Pathologe : Organ der Deutschen Abteilung der Internationalen Akademie für Pathologie, der Deutschen, der Österreichischen und der Schweizerischen Gesellschaft für Pathologie und des Berufsverbandes Deutscher Pathologen. Edited by: Baretton, G B; Bubendorf, L; Büttner, R; Feiden, W; Kreipe, H; Kuhnen, C; Lax, S F; Mentzel, T; Moch, H; Saeger, W; Schirmacher, P; Schmidt, D; Schmitt-Gräff, A; Vieth, M; Werner, M; Schmid, K W (2011). Berlin, DE: Springer.

Huber, G F; Zullig, L; Soltermann, A; Roessle, M; Graf, N; Haerle, S K; Studer, G; Jochum, W; Moch, H; Stoeckli, S J (2011). Down regulation of E-Cadherin (ECAD) - a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx. BMC Cancer, 11:217.

Kristiansen, G; Hu, J; Wichmann, D; Stiehl, D P; Rose, M; Gerhardt, J; Bohnert, A; Ten Haaf, A; Moch, H; Raleigh, J; Varia, M A; Subarsky, P; Scandurra, F M; Gnaiger, E; Gleixner, E; Bicker, A; Gassmann, M; Hankeln, T; Dahl, E; Gorr, T A (2011). Endogenous myoglobin in breast cancer is hypoxia-inducible by alternative transcription and functions to impair mitochondrial activity: a role in tumor suppression? Journal of Biological Chemistry, 286(50):43417-43428.

Fritzsche, F R; Hasler, A; Bode, P K; Adams, H; Seifert, H H; Sulser, T; Moch, H; Barghorn, A; Kristiansen, G (2011). Expression of histone deacetylases 1, 2 and 3 in histological subtypes of testicular germ cell tumours. Histology and Histopathology, 26(12):1555-1561.

Huber, G F; Albinger-Hegyi, A; Soltermann, A; Roessle, M; Graf, N; Haerle, S K; Holzmann, D; Moch, H; Hegyi, I (2011). Expression patterns of Bmi-1 and p16 significantly correlate with overall, disease-specific, and recurrence-free survival in oropharyngeal squamous cell carcinoma. Cancer, 117(20):4659-4670.

Wagner, P L; Stiedl, A C; Wilbertz, T; Petersen, K; Scheble, V; Menon, R; Reischl, M; Mikut, R; Rubin, M A; Fend, F; Moch, H; Soltermann, A; Weder, W; Altorki, N K; Perner, S (2011). Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. Lung Cancer, 74(1):118-123.

Butsch, R; Waelti, S L; Schaerer, S; Braun, J; Korol, D; Probst-Hensch, N; Moch, H; Kurrer, M (2011). Intratumoral plasmacytoid dendritic cells associate with increased survival in patients with follicular lymphoma. Leukemia and Lymphoma, 52(7):1230-1238.

Mortezavi, A; Hermanns, T; Seifert, H H; Baumgartner, M; Provenzano, M; Sulser, T; Burger, M; Montani, M; Ikenberg, K; Hofstaedter, F; Hartmann, A; Jaggi, R; Moch, H; Kristiansen, G; Wild, P J (2011). KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clinical Cancer Research, 17(5):1111-1121.

Blank, P R; Moch, H; Szucs, T D; Schwenkglenks, M (2011). KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clinical Cancer Research, 17(19):6338-6346.

Doberstein, K; Schramme, A; Lee, S B; Blaheta, R A; Wedel, S; Moch, H; Schraml, P; Pfeilschifter, J; Kristiansen, G; Gutwein, P (2011). L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells. Carcinogenesis, 32(3):262-270.

Tischler, V; Pfeifer, M; Hausladen, S; Schirmer, U; Bonde, A K; Kristiansen, G; Sos, M L; Weder, W; Moch, H; Altevogt, P; Soltermann, A (2011). L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Molecular Cancer, 10:127.

Bode, P K; Barghorn, A; Fritzsche, F R; Riener, M O; Kristiansen, G; Knuth, A; Moch, H (2011). MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors. Modern Pathology, 24(6):829-835.

Hammerman, P S; Sos, M L; Ramos, A H; Xu, C; Dutt, A; Zhou, W; Brace, L E; Woods, B A; Lin, W; Zhang, J; Deng, X; Lim, S M; Heynck, S; Peifer, M; Simard, J R; Lawrence, M S; Onofrio, R C; Salvesen, H B; Seidel, D; Zander, T; Heuckmann, J M; Soltermann, A; Moch, H; Koker, M; Leenders, F; Gabler, F; Querings, S; Ansén, S; Brambilla, E; Brambilla, C; Lorimier, P; Brustugun, O T; Helland, A; Petersen, I; Clement, J H; Groen, H; Timens, W; Sietsma, H; Stoelben, E; Wolf, J; Beer, D G; Tsao, M S; Hanna, M; Hatton, C; Eck, M J; Janne, P A; Johnson, B E; Winckler, W; Greulich, H; Bass, A J; Cho, J; Rauh, D; Gray, N S; Wong, K K; Haura, E B; Thomas, R K; Meyerson, M (2011). Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery, 1(1):78-89.

Choschzick, M; Oosterwijk, E; Müller, V; Woelber, L; Simon, R; Moch, H; Tennstedt, P (2011). Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Archiv, 459(2):193-200.

Morra, L; Moch, H (2011). Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. Virchows Archiv, 459(5):465-475.

Dettmer, M; Schmitt, A; Steinert, H; Haldemann, A; Meili, A; Moch, H; Komminoth, P; Perren, A (2011). Poorly differentiated thyroid carcinomas: How much poorly differentiated is needed? American Journal of Surgical Pathology, 35(12):1866-1872.

Blyszczuk, P; Germano, D; Stein, S; Moch, H; Matter, C M; Beck-Schimmer, B; Lüscher, T F; Eriksson, U; Kania, G (2011). Profibrotic potential of Prominin-1+ epithelial progenitor cells in pulmonary fibrosis. Respiratory Research, 12:126.

Viehl, C T; Langer, I; Guller, U; Zanetti-Dällenbach, R; Moch, H; Wight, E; Oertli, D; Zuber, M (2011). Prognostic impact and therapeutic implications of sentinel lymph node micro-metastases in early-stage breast cancer patients. Journal of Surgical Oncology, 103(6):531-533.

Morra, L; Rechsteiner, M; Casagrande, S; Duc Luu, V; Santimaria, R; Diener, P A; Sulser, T; Kristiansen, G; Schraml, P; Moch, H; Soltermann, A (2011). Relevance of periostin splice variants in renal cell carcinoma. American Journal of Pathology, 179(3):1513-1521.

Maier, S; Wilbertz, T; Braun, M; Scheble, V; Reischl, M; Mikut, R; Menon, R; Nikolov, P; Petersen, K; Beschorner, C; Moch, H; Kakies, C; Protzel, C; Bauer, J; Soltermann, A; Fend, F; Staebler, A; Lengerke, C; Perner, S (2011). SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. Human Pathology, 42(8):1078-1088.

Wilbertz, T; Wagner, P; Petersen, K F; Stiedl, A C; Scheble, V J; Maier, S; Reischl, M; Mikut, R; Altorki, N K; Moch, H; Fend, F; Staebler, A; Bass, A J; Meyerson, M; Rubin, M A; Soltermann, A; Lengerke, C; Perner, S (2011). SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Modern Pathology, 24(7):944-953.

Fritzsche, F R; Pianca, S; Gaspert, A; Varga, Z; Wang, L; Farrell, M P; Chen, X B; Hirsch, H H; Springer, E; Fehr, T; Myles, J; Tubbs, R; Moch, H (2011). Silver-enhanced in situ hybridization for detection of polyomavirus DNA in patients with BK virus nephropathy. Diagnostic Molecular Pathology, 20(2):105-110.

Theurillat, J P; Metzler, S C; Henzi, N; Djouder, N; Helbling, M; Zimmermann, A K; Jacob, F; Soltermann, A; Caduff, R; Heinzelmann-Schwarz, V; Moch, H; Krek, W (2011). URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell, 19(3):317-332.

Rechsteiner, M P; von Teichman, A; Nowicka, A; Sulser, T; Schraml, P; Moch, H (2011). VHL gene mutations and their effects on hypoxia inducible factor HIF{alpha}: Identification of potential driver and passenger mutations. Cancer Research, 71(16):5500-5511.

Teichman, A V; Compérat, E; Behnke, S; Storz, M; Moch, H; Schraml, P (2011). VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma. Modern Pathology, 24(4):571-578.

Giger, O; Caduff, R; O'Meara, A; Diener, P A; Knuth, A; Jäger, D; Moch, H; Varga, Z (2010). Frequent expression of the breast differentiation antigen NY-BR-1 in mammary and extramammary Paget's disease. Pathology international, 60(11):726-734.

Kristiansen, G; Rose, M; Geisler, C; Fritzsche, F R; Gerhardt, J; Lüke, C; Ladhoff, A-M; Knüchel, R; Dietel, M; Moch, H; Varga, Z; Theurillat, J-P; Gorr, T A; Dahl, E (2010). Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype. British Journal of Cancer, 102(12):1736-1745.

Albinger-Hegyi, A; Stoeckli, S J; Schmid, S; Storz, M; Iotzova, G; Probst-Hensch, N M; Rehrauer, H; Tinguely, M; Moch, H; Hegyi, I (2010). Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). International Journal of Cancer, 126(11):2653 -2662.

Moch, H (2010). Cystic renal tumors: new entities and novel concepts. Advances in Anatomic Pathology, 17(3):209-14.

Schramm, A; Opitz, I; Thies, S; Seifert, B; Moch, H; Weder, W; Soltermann, A (2010). Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. European Journal of Cardio-Thoracic Surgery, 37(3):566-572.

Paner, G P; Amin, M B; Alvarado-Cabrero, I; Young, A N; Stricker, H J; Moch, H; Lyles, R H (2010). A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. American Journal of Surgical Pathology, 34(9):1233-1240.

Leuenberger, M; Frigerio, S; Wild, P J; Noetzli, F; Korol, D; Zimmermann, D R; Gengler, C; Probst-Hensch, N M; Moch, H; Tinguely, M (2010). AID protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with poor prognosis and complex genetic alterations. Modern Pathology, 23(2):177-186.

Sutter, R; Shakhova, O; Bhagat, H; Behesti, H; Sutter, C; Penkar, S; Santuccione, A; Bernays, R L; Heppner, F L; Schüller, U; Grotzer, M; Moch, H; Schrami, P; Marino, S (2010). Cerebellar stem cells act as medulloblastoma-initiating cells in a mouse model and a neural stem cell signature characterizes a subset of human medulloblastomas. Oncogene, 29(12):1845-1856.

Theurillat, J P; Dreier, B; Nagy-Davidescu, G; Seifert, Burkhardt; Behnke, S; Zürrer-Härdi, U; Ingold, F; Plückthun, A; Moch, H (2010). Designed ankyrin repeat proteins: a novel tool for testing epidermal growth factor receptor 2 expression in breast cancer. Modern Pathology, 23(9):1289-1297.

Fritzsche, F R; Bode, P K; Moch, H; Kristiansen, G; Varga, Z; Bode, B (2010). Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH). American Journal of Surgical Pathology, 34(8):1180-1185.

Soltermann, A; Opitz, I; Tischler, V; Thies, S; Morra, L; Stahel, R A; Weder, W; Moch, H (2010). EMT in NSCLC and malignant pleural mesothelioma. memo - Magazine of European Medical Oncology, 3(4):180-184.

Riener, M O; Fritzsche, F R; Soll, C; Pestalozzi, B C; Probst-Hensch, N M; Clavien, P A; Jochum, W; Soltermann, A; Moch, H; Kristiansen, G (2010). Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. Histopathology, 56(5):600-606.

Schmid, S; Tinguely, M; Cione, P; Moch, H; Bode, B (2010). Flow cytometry as an accurate tool to complement fine needle aspiration cytology in the diagnosis of low grade malignant lymphomas. Cytopathology, 22(6):397-406.

Weiss, J; Sos, M L; Seidel, D; et al; Soltermann, A; Moch, H (2010). Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine, 2(62):62ra93.

Blank, P R; Schwenkglenks, M; Moch, H; Szucs, T D (2010). Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. Breast Cancer Research and Treatment, 124(2):497-507.

Probst-Hensch, N M; Steiner, J H B; Schraml, P; Varga, Z; Zürrer-Härdi, U; Storz, M; Korol, D; Fehr, M K; Fink, D; Pestalozzi, B C; Lütolf, U M; Theurillat, J P; Moch, H (2010). IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clinical Cancer Research, 16(3):1025-1032.

Ikenberg, K; Fritzsche, F R; Zuerrer-Haerdi, U; Hofmann, I; Hermanns, T; Seifert, H; Müntener, M; Provenzano, M; Sulser, T; Behnke, S; Gerhardt, J; Mortezavi, A; Wild, P; Hofstädter, F; Burger, M; Moch, H; Kristiansen, G (2010). Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores. BMC Cancer, 10:341.

Weber, A; Zimmermann, D R; Moch, H (2010). KRAS-Mutationsstatus und kolorektales Karzinom - Diagnostik. In: Köberle, D; Gautschi, O. KRAS-Mutationsstatus und kolorektales Karzinom. Bremen: UNI-MED Science, UNI-MED Verlag AG, 29-33.

Dahinden, C; Ingold, B; Wild, P; Boysen, G; Luu, V D; Montani, M; Kristiansen, G; Sulser, T; Bühlmann, P; Moch, H; Schraml, P (2010). Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clinical Cancer Research, 16(1):88-98.

Studer, A M; Limbach, L K; Van Duc, L; Krumeich, F; Athanassiou, E K; Gerber, L C; Moch, H; Stark, W J (2010). Nanoparticle cytotoxicity depends on intracellular solubility: comparison of stabilized copper metal and degradable copper oxide nanoparticles. Toxicology Letters, 197(3):169-174.

Fritzsche, F R; Reineke, T; Morawietz, L; Kristiansen, G; Dietel, M; Fink, D; Rageth, C; Honegger, C; Caduff, R; Moch, H; Varga, Z (2010). Pathological processing techniques and final diagnosis of breast cancer sentinel lymph nodes. Annals of Surgical Oncology, 17(11):2892-2898.

Akaza, H; Lopez-Beltran, A; Martignoni, G; Moch, H; Montironi, R; Reuter, V E (2010). Pathology of Renal Cancer. In: Kirkali, Z; Mulders, P. 1st EAU-ICD International Consultation on Kidney Cancer. Barcelona, 47-72.

Tischler, V; Fritzsche, F R; Wild, P J; Stephan, C; Seifert, H H; Riener, M O; Hermanns, T; Mortezavi, A; Gerhardt, J; Schraml, P; Jung, K; Moch, H; Soltermann, A; Kristiansen, G (2010). Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer, 10:273.

Nilsson, K P R; Ikenberg, K; Aslund, A; Fransson, S; Konradsson, P; Röcken, C; Moch, H; Aguzzi, A (2010). Structural typing of systemic amyloidoses by luminescent-conjugated polymer spectroscopy. American Journal of Pathology, 176(2):563-574.

Cueni, L N; Hegyi, I; Shin, J W; Albinger-Hegyi, A; Gruber, S; Kunstfeld, R; Moch, H; Detmar, M (2010). Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. American Journal of Pathology, 177(2):1004-1016.

Montani, M; Heinimann, K; von Teichman, A; Rudolph, T; Perren, A; Moch, H (2010). VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. The American Journal of Surgical Pathology, 34(6):806-815.

Moch, H (2010). Zystische Nierentumoren. Neue Tumortypen und aktuelle molekulare Erkenntnisse. Der Pathologe, 31(Sup 2):239-243.

Fritzsche, F R; Kristiansen, G; Frauenfelder, T; Opitz, I; Bode, P; Moch, H; Montani, M (2009). Large mixed germ cell tumor in a young patient presenting as an intrapulmonary mass. Pathology - Research and Practice, 205(8):572-578.

Langer, I; Guller, U; Hsu-Schmitz, S F; Ladewig, A; Viehl, C T; Moch, H; Wight, E; Harder, F; Oertli, D; Zuber, M (2009). Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients. European Journal of Surgical Oncology, 35(8):805-813.

Wild, P J; Fuchs, T; Stoehr, R; Zimmermann, D; Frigerio, S; Padberg, B; Steiner, I; Zwarthoff, E C; Burger, M; Denzinger, S; Hofstaedter, F; Kristiansen, G; Hermanns, T; Seifert, H H; Provenzano, M; Sulser, T; Roth, V; Buhmann, J M; Moch, H; Hartmann, A (2009). Detection of Urothelial Bladder Cancer Cells in Voided Urine Can Be Improved by a Combination of Cytology and Standardized Microsatellite Analysis. Cancer Epidemiology Biomarkers & Prevention, 18(6):1798-1806.

Balamurugan, K; Luu, V D; Kaufmann, M R; Hofmann, V S; Boysen, G; Barth, S; Bordoli, M R; Stiehl, D P; Moch, H; Schraml, P; Wenger, R H; Camenisch, G (2009). Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response. Oncogene:1-12.

Zellweger, T; Günther, S; Zlobec, I; Savic, S; Sauter, G; Moch, H; Mattarelli, G; Eichenberger, T; Curschellas, E; Rüfenacht, H; Bachmann, A; Gasser, T C; Mihatsch, M J; Bubendorf, L (2009). Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. International Journal of Cancer, 124(9):2116-2123.

Dellas, A; Jundt, G; Sartorius, G; Schneider, M; Moch, H (2009). Combined PTEN and p27kip1 protein expression patterns are associated with obesity and prognosis in endometrial carcinomas. Clinical Cancer Research, 15(7):2456-2462.

Gutwein, P; Schramme, A; Voss, B; Abdel-Bakky, M S; Doberstein, K; Ludwig, A; Altevogt, P; Hansmann, M L; Moch, H; Kristiansen, G; Pfeilschifter, J (2009). Downregulation of junctional adhesion molecule-A is involved in the progression of clear cell renal cell carcinoma. Biochemical and Biophysical Research Communications (BBRC), 380(2):387-391.

Anlauf, M; Bauersfeld, J; Raffel, A; Koch, C A; Henopp, T; Alkatout, I; Schmitt, A; Weber, A; Kruse, M L; Braunstein, S; Kaserer, K; Brauckhoff, M; Dralle, H; Moch, H; Heitz, P U; Komminoth, P; Knoefel, W; Perren, A; Klöppel, G (2009). Insulinomatosis: a multicentric insulinoma disease that frequently causes early recurrent hyperinsulinemic hypoglycemia. American Journal of Surgical Pathology, 33(3):339-346.

Issa, R M; Lebeau, A; Grob, T; Holst, F; Moch, H; Terracciano, L; Choschzick, M; Sauter, G; Simon, R (2009). Estrogen receptor gene amplification occurs rarely in ovarian cancer. Modern Pathology, 22(2):191-196.

Riener, M O; Stenner, F; Liewen, H; Soll, C; Breitenstein, S; Pestalozzi, B C; Samaras, P; Probst-Hensch, N M; Hellerbrand, C; Müllhaupt, B; Clavien, P A; Bahra, M; Neuhaus, P; Wild, P; Fritzsche, F; Moch, H; Jochum, W; Kristiansen, G (2009). Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology, 49(5):1602 -1609.

Langer, I; Guller, U; Berclaz, G; Koechli, O R; Moch, H; Schaer, G; Fehr, M K; Hess, T; Oertli, D; Bronz, L; Schnarwyler, B; Wight, E; Uehlinger, U; Infanger, E; Burger, D; Zuber, M (2009). Accuracy of frozen section of sentinel lymph nodes: a prospective analysis of 659 breast cancer patients of the Swiss multicenter study. Breast Cancer Research and Treatment, 113(1):129-136.

Vasei, M; Modjtahedi, H; Ale-Booyeh, O; Mosallaei, A; Kajbafzadeh, A M; Shahriari, M; Ghaderi, A A; Soleymanpour, H; Kosari, F; Moch, H; Sauter, G (2009). Amplification and expression of EGFR and ERBB2 in Wilms tumor. Cancer Genetics and Cytogenetics, 194(2):88-95.

Kellner, A; Matschke, J; Bernreuther, C; Moch, H; Ferrer, I; Glatzel, M (2009). Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Annals of Neurology, 65(1):24-31.

Langer, I; Guller, U; Viehl, C T; Moch, H; Wight, E; Harder, F; Oertli, D; Zuber, M (2009). Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Annals of Surgical Oncology, 16(12):3366-3374.

Tölle, A; Jung, M; Lein, M; Johannsen, M; Miller, K; Moch, H; Jung, K; Kristiansen, G (2009). Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? BMC Cancer, 9:248.

Giobbie-Hurder, A; Price, K N; Gelber, R D; et al; Varga, Z; Moch, H; Caduff, R (2009). Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clinical Trials, 6(3):272-287.

Eichelberg, C; Junker, K; Ljungberg, B; Moch, H (2009). Diagnostic and Prognostic Molecular Markers for Renal Cell Carcinoma: A Critical Appraisal of the Current State of Research and Clinical Applicability. European Urology, 55(4):851-863.

Kempkensteffen, C; Fritzsche, F R; Johannsen, M; Weikert, S; Hinz, S; Dietel, M; Riener, M O; Moch, H; Jung, K; Krause, H; Miller, K; Kristiansen, G (2009). Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer. BMC Cancer, 9:276.

Riener, M O; Wild, P J; Soll, C; Knuth, A; Jin, B; Jungbluth, A; Hellerbrand, C; Clavien, P A; Moch, H; Jochum, W (2009). Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. International Journal of Cancer, 124(2):352-357.

Sørensen, K D; Wild, P J; Mortezavi, A; Adolf, K; Tørring, N; Heebøll, S; Ulhøi, B P; Ottosen, P; Sulser, T; Hermanns, T; Moch, H; Borre, M; Ørntoft, T F; Dyrskjøt, L (2009). Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clinical Cancer Research, 15(4):1400-1410.

Floros, X; Fuchs, T J; Rechsteiner, M P; Spinas, G; Moch, H; Buhmann, J M (2009). Graph-based pancreatic islet segmentation for early type 2 diabetes mellitus on histopathological tissue. In: Yang, G Z; Hawkes, D; Rueckert, D; Noble, A; Taylor, C. Medical Image Computing and Computer-Assisted Intervention – MICCAI 2009, 12th International Conference, London, UK, September 20-24, 2009, Proceedings, Part 2. Berlin: Springer, 633-640.

Ingold, B; Schraml, P; Heppner, F L; Moch, H (2009). Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. PLoS ONE, 4(3):e4775.

Boysen, G; Wollscheid, B; Bausch-Fluck, D; Schraml, P; Moch, H (2009). Identifizierung VHL-assoziierter Veränderungen im klarzelligen Nierenzellkarzinom : Anwendung von kombinierten Genom- und Expressionsanalysen. Der Pathologe, Suppl 2:188-192.

Soltermann, A; Moch, H (2009). Klinisch relevante Biomarker des nicht kleinzelligen Lungenkarzinoms. Diagnostik, Prognose, Therapie und Prävention. The Medical Journal (TMJ), 2009(4):26-29.

Luu, V D; Boysen, G; Struckmann, K; Casagrande, S; von Teichman, A; Wild, P J; Sulser, T; Schraml, P; Moch, H (2009). Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. Clinical Cancer Research, 15(10):3297-3304.

Ghadjar, P; Blank-Liss, W; Simcock, M; Hegyi, I; Beer, K T; Moch, H; Aebersold, D M; Zimmer, Y (2009). MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. Clinical and Experimental Metastasis, 26(7):809-815.

Beroukhim, R; Brunet, J P; Di Napoli, A; Mertz, K D; Seeley, A; Pires, M M; Linhart, D; Worrell, R A; Moch, H; Rubin, M A; Sellers, W R; Meyerson, M; Linehan, W M; Kaelin, W G; Signoretti, S (2009). Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Research, 69(11):4674-4681.

Gerstung, M; Baudis, M; Moch, H; Beerenwinkel, N (2009). Quantifying cancer progression with conjunctive Bayesian networks. Bioinformatics, 25(21):2809-2815.

Fuchs, T J; Haybaeck, J; Wild, P J; Heikenwalder, M; Moch, H; Aguzzi, A; Buhmann, J M (2009). Randomized tree ensembles for object detection in computational pathology. In: Bebis, G; et al. Advances in Visual Computing : 5th International Symposium, ISVC 2009, Las Vegas, NV, USA, November 30 - December 2, 2009, Proceedings, Part 1. Berlin: Springer, 367-380.

Moch, H; Artibani, W; Delahunt, B; Ficarra, V; Knuechel, R; Montorsi, F; Patard, J J; Stief, C G; Sulser, T; Wild, P J (2009). Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. European Urology, 56(4):636-643.

Perner, S; Wagner, P L; Soltermann, A; LaFargue, C; Tischler, V; Weir, B A; Weder, W; Meyerson, M; Giordano, T J; Moch, H; Rubin, M A (2009). TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. Journal of Pathology, 217(1):65-72.

Schmitt, A M; Schmid, S; Rudolph, T; Anlauf, M; Prinz, C; Klöppel, G; Moch, H; Heitz, P U; Komminoth, P; Perren, A (2009). VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocrine-Related Cancer, 16(4):1219-1227.

Thoma, C R; Toso, A; Gutbrodt, K L; Reggi, S P; Frew, I J; Schraml, Peter; Hergovich, A; Moch, H; Meraldi, P; Krek, W (2009). VHL loss causes spindle misorientation and chromosome instability. Nature Cell Biology, 11(8):994-1001.

Soltermann, A; Tischler, V; Arbogast, S; Braun, J; Probst-Hensch, N M; Weder, W; Moch, H; Kristiansen, G (2008). Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clinical Cancer Research, 14(22):7430-7437.

Moch, H (2008). Funktionen des VHL-Proteins bei Entstehung und Progression von Nierenzellkarzinomen. Der Pathologe, 29(Suppl.):149-152.

Moch, H (2008). Molekulare Basis der zielgerichteten Therapien bei metastasierenden Nierenzellkarzinomen. Der Pathologe, 29(Suppl.):184-186.

Waibel, R; Treichler, H; Schaefer, N G; van Staveren, D R; Mundwiler, S; Kunze, S; Küenzi, M; Alberto, R; Nüesch, J; Knuth, A; Moch, H; Schibli, R; Schubiger, P A (2008). New derivatives of vitamin B12 show preferential targeting of tumors. Cancer Research, 68(8):2904-2911.

Tinguely, M; Jenni, B; Knights, A; Lopes, B; Korol, D; Rousson, V; Curioni Fontecedro, A; Cogliatti, S B; Bittermann, A G; Schmid, U; Dommann-Scherrer, C; Maurer, R; Renner, C; Probst-Hensch, N M; Moch, H; Knuth, A; Zippelius, A (2008). MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer Science, 99(4):720-725.

Varga, Z; Rageth, C; Saurenmann, E; Honegger, C; von Orelli, S; Fehr, M; Fink, D; Seifert, Burkhardt; Moch, H; Caduff, R (2008). Use of intraoperative stereomicroscopy for preventing loss of metastases during frozen sectioning of sentinel lymph nodes in breast cancer. Histopathology, 52(5):597-604.

Curioni-Fontecedro, A; Knights, A J; Tinguely, M; Nuber, N; Schneider, C; Thomson, C W; von Boehmer, I; Bossart, W; Pahlich, S; Gehring, H; Moch, H; Renner, C; Knuth, A; Zippelius, A (2008). MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma. Leukemia, 22(8):1646-1648.

Steu, S; Baucamp, M; von Dach, G; Bawohl, M; Dettwiler, S; Storz, M; Moch, H; Schraml, P (2008). A procedure for tissue freezing and processing applicable to both intra-operative frozen section diagnosis and tissue banking in surgical pathology. Virchows Archiv, 452(3):305-312.

Zhao, J; Moch, H (2008). Absence of JH2 domain mutation of the tyrosine kinase JAK2 in renal cell carcinomas. Acta Oncologica, 47(3):474-476.

Mertz, K D; Demichelis, F; Sboner, A; Hirsch, M S; Cin, P D; Struckmann, K; Storz, M; Scherrer, S; Schmid, D M; Strebel, R T; Probst-Hensch, N M; Gerstein, M; Moch, H; Rubin, M A (2008). Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer. International Journal of Cancer, 123(3):569-576.

Fritzsche, F R; Oelrich, B; Johannsen, M; Kristiansen, I; Moch, H; Jung, K; Kristiansen, G (2008). Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. Clinical Cancer Research, 14(21):7035-7042.

Frew, I J; Minola, A; Georgiev, S; Hitz, M; Moch, H; Richard, S; Vortmeyer, A O; Krek, W (2008). Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia. Molecular and Cellular Biology, 28(14):4536-4548.

Fuchs, T J; Wild, P J; Moch, H; Buhmann, J M (2008). Computational pathology analysis of tissue microarrays predicts survival of renal clear cell carcinoma patients. In: Metaxas, D. Medical Image Computing and Computer-Assisted Intervention – MICCAI 2008. Pt. 2. Berlin: Springer, 1-8.

Zhao, J; Leonard, C; Gemsenjäger, E; Heitz, P U; Moch, H; Odermatt, B (2008). Differentiation of human follicular thyroid adenomas from carcinomas by gene expression profiling. Oncology Reports, 19(2):329-337.

Theurillat, J P; Zürrer-Härdi, U; Varga, Z; Barghorn, A; Saller, E; Frei, C; Storz, M; Behnke, S; Seifert, Burkhardt; Fehr, M; Fink, D; Rageth, C; Linsenmeier, C; Pestalozzi, B; Chen, Y T; Knuth, A; Jäger, D; Moch, H (2008). Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts. International Journal of Cancer, 122(7):1585-1591.

Fritzsche, F R; Riener, M O; Dietel, M; Moch, H; Jung, K; Kristiansen, G (2008). GOLPH2 expression in renal cell cancer. BMC Urology, 8:15.

Kristiansen, G; Fritzsche, F R; Wassermann, K; Jäger, C; Tölle, A; Lein, M; Stephan, C; Jung, K; Pilarsky, C; Dietel, M; Moch, H (2008). GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. British Journal of Cancer, 99(6):939-948.

Reschke, M; Mihic-Probst, D; van der Horst, E H; Knyazev, P; Wild, P J; Hutterer, M; Meyer, S; Dummer, R; Moch, H; Ullrich, A (2008). HER3 is a determinant for poor prognosis in melanoma. Clinical Cancer Research, 14(16):5188-5197.

Vasei, M; Moch, H; Mousavi, A; Kajbafzadeh, A M; Sauter, G (2008). Immunohistochemical profiling of Wilms tumor: a tissue microarray study. Applied Immunohistochemistry & Molecular Morphology, 16(2):128-134.

Tinguely, M; Hofmann, A; Bausch-Fluck, D; Moch, H; Wollscheid, B (2008). Immunophenotyping without antibodies. New perspectives for lymphoma characterization. Der Pathologe, 29 Suppl:314-316.

Tinguely, M; Hofmann, A; Bausch-Fluck, D; Moch, H; Wollscheid, B (2008). Immunphänotypisierung ohne Antikörper: Neue Perspektiven in der Lymphomcharakterisierung. Der Pathologe, 29(Suppl.):314-316.

Schmitt, A M; Riniker, F; Anlauf, M; Schmid, S; Soltermann, A; Moch, H; Heitz, P U; Klöppel, G; Komminoth, P; Perren, A (2008). Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. American Journal of Surgical Pathology, 32(3):420-425.

Soltermann, A; Ossola, R; Kilgus-Hawelski, S; von Eckardstein, A; Suter, T; Aebersold, R; Moch, H (2008). N-glycoprotein profiling of lung adenocarcinoma pleural effusions by shotgun proteomics. Cancer, 114(2):124-133.

Nizze, H; Kerjaschki, D; Moch, H (2008). Niere. In: Böcker, W; et al. Pathologie. München, DE: Elsevier, Urban & Fischer, 853-888.

Lebeau, A; Grob, T J; Holst, F; Seyedi-Fazlollahi, N; Moch, H; Terracciano, L; Turzynski, A; Choschzick, M; Sauter, G; Simon, R (2008). Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. Journal of Pathology, 216(2):151-157.

Opitz, I; Soltermann, A; Abaecherli, M; Hinterberger, M; Probst-Hensch, N; Stahel, R; Moch, H; Weder, W (2008). PTEN expression is a strong predictor of survival in mesothelioma patients. European Journal of Cardio-Thoracic Surgery, 33(3):502-506.

Pathologie. Edited by: Böcker, W; Denk, H; Heitz, P U; Moch, H (2008). München, DE: Elsevier, Urban & Fischer.

Moch, H; Komminoth, P; Zimmermann, D R; Odermatt, B; Probst-Hensch, N M; Bopp, M (2008). Pathologie: Aufgaben und Methoden. In: Böcker, W; Denk, H; Heitz, P U. Pathologie. München, Jena: Urban und Fischer bei Elsevier, 3-34.

Ingold, B; Wild, P J; Nocito, A; Amin, M B; Storz, M; Heppner, F L; Moch, H (2008). Renal cell carcinoma marker reliably discriminates central nervous system haemangioblastoma from brain metastases of renal cell carcinoma. Histopathology, 52(6):674-681.

Repetitorium Pathologie. Edited by: Böcker, W; Denk, H; Heitz, P U; Moch, H (2008). München, DE: Elsevier, Urban & Fischer.

Garbrecht, N; Anlauf, M; Schmitt, A; Henopp, T; Sipos, B; Raffel, A; Eisenberger, C F; Knoefel, W T; Pavel, M; Fottner, C; Musholt, T J; Rinke, A; Arnold, R; Berndt, U; Plöckinger, U; Wiedenmann, B; Moch, H; Heitz, P U; Komminoth, P; Perren, A; Klöppel, G (2008). Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocrine-Related Cancer, 15(1):229-241.

Schraml, P; Frew, I J; Thoma, C R; Boysen, G; Struckmann, K; Krek, W; Moch, H (2008). Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. Modern Pathology, 22(1):31-36.

Stallmach, T; Klöppel, G; Roth, J; Spinas, G A (2008). Stoffwechselerkrankungen. In: Böcker, W; Denk, H; Heitz, P U; Moch, H. Pathologie. München: Urban und Fischer, 1123-1147.

Luu, V D; Fischer, B; von Teichman, A; Boysen, G; Mertz, K; Zimmermann, P; Moch, H; Schraml, P (2008). Von-Hippel-Lindau-Gen-Mutationstypen: Assoziation mit Genexpressionssignaturen in klarzelligen Nierenzellkarzinomen. Der Pathologe, 29(Suppl.):303-307.

Fuchs, T J; Lange, T; Wild, P J; Moch, H; Buhmann, J M (2008). Weakly supervised cell nuclei detection and segmentation on tissue microarrays of renal clear cell carcinoma. In: Rigoll, G. Pattern Recognition. Berlin, DE: Springer, 173-182.

Frew, I J; Thoma, C R; Georgiev, S; Minola, A; Hitz, M; Montani, M; Moch, H; Krek, W (2008). pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO Journal, 27(12):1747-1757.

Struckmann, K; Mertz, K; Steu, S; Storz, M; Staller, P; Krek, W; Schraml, P; Moch, H (2008). pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. Journal of Pathology, 214(4):464-471.

Theurillat, J P; Zürrer-Härdi, U; Varga, Z; Storz, M; Probst-Hensch, N M; Seifert, Burkhardt; Fehr, M K; Fink, D; Ferrone, S; Pestalozzi, B; Jungbluth, A A; Chen, Y T; Jäger, D; Knuth, A; Moch, H (2007). NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunology, Immunotherapy, 56(11):1723-1731.

Bode-Lesniewska, B; Frigerio, S; Exner, U; Abdou, M T; Moch, H; Zimmermann, D R (2007). Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion. Genes, Chromosomes and Cancer, 46(11):961-971.

Dietel, M; Ellis, I O; Höfler, H; Kreipe, H; Moch, H; Dankof, A; Kölble, K; Kristiansen, G (2007). Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Archiv, 451(1):19-25.

Zhao, J; Yart, A; Frigerio, S; Perren, A; Schraml, P; Weisstanner, C; Stallmach, T; Krek, W; Moch, H (2007). Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene. Oncogene, 26(23):3440-3449.

Mihic-Probst, D; Kuster, A; Kilgus, S; Bode-Lesniewska, B; Ingold-Heppner, B; Leung, C; Storz, M; Seifert, Burkhardt; Marino, S; Schraml, P; Dummer, R; Moch, H (2007). Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. International Journal of Cancer, 121(8):1764-1770.

Ceschi, M; Gutzwiller, Felix; Moch, H; Eichholzer, Monika; Probst-Hensch, N M (2007). Epidemiology and pathophysiology of obesity as cause of cancer. Swiss Medical Weekly, 137(3-4):50-56.

Theurillat, J P; Ingold, F; Freitag, C; Zippelius, A; Varga, Z; Seifert, Burkhardt; Chen, Y T; Jäger, D; Knuth, A; Moch, H (2007). NY-ESO-1 protein expression in primary breast carcinoma and metastases - correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. International Journal of Cancer, 120(11):2411-2417.

Varga, Z; Rageth, C; Saurenmann, E; Honegger, C; von Orelli, S; Fehr, M; Fink, D; Seifert, Burkhardt; Moch, H; Caduff, R (2007). Potentieller Verlust von Metastasen in Sentinel Lymphknoten während der Schnellschnitt Untersuchung. Verhandlungen der Deutschen Gesellschaft für Pathologie, 91:221-224.

Mertz, K D; Tchinda, J; Küfer, R; Möller, P; Rubin, M A; Moch, H; Perner, S (2006). Cytogenetic alterations in renal tumors. Applications for comparative genomic hybridization and fluorescence in situ hybridization. Der Urologe. Ausg. A, 45(3):316-322.

Mihic-Probst, D; Mnich, C D; Oberholzer, P A; Seifert, Burkhardt; Sasse, B; Moch, H; Dummer, R (2006). p16 expression in primary malignant melanoma is associated with prognosis and lymph node status. International Journal of Cancer, 118(9):2262-2268.

Moch, H (2005). Aktuelle Klassifikation der Nierentumoren – Was ist wissenswert für die Praktiker? Praxis, 94(33):1261-1265.

Glatzel, M; Ott, P M; Linder, T; Gebbers, J O; Gmür, A; Wüst, W; Huber, G; Moch, H; Podvinec, M; Stamm, B; Aguzzi, A (2003). Human prion diseases: epidemiology and integrated risk assessment. Lancet Neurology, 2(12):757-763.

This list was generated on Wed Dec 13 15:03:57 2017 CET.